HitGen Inc. (SHA:688222)

China · Delayed Price · Currency is CNY

35.87

+2.42 (7.23%)

At close: Jul 10, 2026

111.87% (1Y)

Market Cap	14.37B +121.0%
Revenue (ttm)	579.37M +35.9%
Net Income	122.72M +86.8%
EPS	0.30 +73.8%
Shares Out	400.68M
PE Ratio	119.34
Forward PE	105.50
Dividend	0.13 (0.36%)
Ex-Dividend Date	Jun 18, 2026

Volume	33,818,051
Open	32.90
Previous Close	33.45
Day's Range	32.60 - 36.90
52-Week Range	16.75 - 42.98
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About HitGen

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline also includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 546

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688222

Full Company Profile

Financial Performance

In 2025, HitGen's revenue was 525.57 million, an increase of 23.09% compared to the previous year's 426.99 million. Earnings were 109.51 million, an increase of 113.22%.

Financial Statements